Literature DB >> 15554275

Interstitial cystitis in persistent posthysterectomy chronic pelvic pain.

Maurice K Chung1.   

Abstract

OBJECTIVES: Hysterectomies may be performed unnecessarily in women with chronic pelvic pain if the diagnosis of interstitial cystitis is not considered. The objectives of this study were to investigate the prevalence of interstitial cystitis in patients with posthysterectomy chronic pelvic pain and to evaluate the efficacy of various therapies for interstitial cystitis.
METHODS: A study was performed of 111 patients with chronic pelvic pain whose pain persisted after hysterectomy. Patients were screened with the Pelvic Pain and Urgency/Frequency symptom scale, and underwent Potassium Sensitivity Testing. Patients were treated with dietary changes alone or in combination with cystoscopic hydrodistention or oral pentosan polysulfate, or both of these, for 3 to 6 months.
RESULTS: Of the 111 patients enrolled, 79% (n=88) were diagnosed with bladder dysfunction consistent with interstitial cystitis. For patients treated with dietary modification alone (n=33), the mean score on the Pelvic Pain and Urgency/Frequency questionnaire improved 15.4%, from 13.18 at baseline to 11.15 at follow-up. For patients treated with pentosan polysulfate or cystoscopic hydrodistention, or both, plus diet changes (n=78), Pelvic Pain and Urgency/Frequency scores improved 34.2%, from 15.01 to 9.87.
CONCLUSION: In this study, nonsurgical treatment for interstitial cystitis resulted in a marked improvement in symptoms that had not improved with surgery. Without determining the origin of bladder pain, gynecologists should not proceed to hysterectomy in patients with chronic pelvic pain.

Entities:  

Mesh:

Year:  2004        PMID: 15554275      PMCID: PMC3016837     

Source DB:  PubMed          Journal:  JSLS        ISSN: 1086-8089            Impact factor:   2.172


INTRODUCTION

Chronic pelvic pain (CPP), defined as nonmenstrual pelvic pain that occurs for more than 6 months, is a debilitating condition that affects approximately 9 million women in the United States.[1,2] Chronic pelvic pain can have multiple causes, including disorders of the reproductive tract, gastrointestinal system, urologic organs, the musculoskeletal system, and the psychoneurological system.[2] Therefore, this condition is often difficult to diagnose accurately and is frustrating to treat.[3] Of the approximately 600,000 hysterectomies performed annually in the United States, 10% to 20% result from a diagnosis of CPP.[2,4-7] Although hysterectomy is often effective for the relief of symptoms associated with CPP, several studies indicate that up to 38% of women report persistent postoperative CPP.[3,6,8,9] In those patients with persistent posthysterectomy CPP, often no evidence is present of uterine pathology on postoperative examination.[2] This evidence suggests that hysterectomies may be performed unnecessarily in some patients with CPP. The Maryland Women's Health Study, a large 2-year prospective study of 1299 women, was designed to assess the efficacy of hysterectomies in benign conditions, including pelvic pain.[8] Over the 2-year posthysterectomy follow-up period, patients experienced a substantial improvement in symptoms, including pelvic pain (.[8] Although many patients had postoperative improvements, 8.5% of patients had persistent pelvic pain at 1 year posthysterectomy.[8] Another large prospective study, the Maine Women's Health Study, examined the rate of relief for specific symptoms in 418 women who had a hysterectomy for any nonmalignant condition.[6] One year after surgery, persistent pelvic pain was reported in 5% of patients who had some degree of pelvic pain before hysterectomy.[6] In both the Maine and Maryland studies, problems with urination (frequency, urgency, or incontinence) persisted in approximately 9% of patients.[6,8] Symptom Improvement Data From the Maryland Women's Health Study (N = 1299)*[8] Values are percentages unless otherwise indicated. Two additional studies evaluated patient outcomes after hysterectomy. In a study by Hillis et al[9] of 308 women who underwent hysterectomy for CPP, 279 of whom were available for follow-up at 1 year, 21% (58/279) reported continued but decreased pain. Of the total study cohort of 308, 5%[15] reported that their pain was unchanged (2.5%, 7) or increased (2.5%, 8). Among the subset of 63 patients with no histopathologic abnormalities of the uterus or adnexa, 38.1% (24/63) reported persistent pain after 1 year, including 9.5% (6/63) with pain that had increased or was unchanged.[9] In a study by Stovall et al[3] involving 99 patients who underwent hysterectomy for CPP, 22% (22/99) reported persistent pain following the procedure. These results suggest that the source of CPP may be nongynecologic in many cases and may not require surgical intervention. In clinical practice, endometriosis, abdominal/pelvic adhesions, irritable bowel syndrome, and interstitial cystitis (IC) are most frequently associated with CPP.[2] Symptoms of IC, in particular, may mimic gynecologic disorders, and include voiding symptoms, dyspareunia, flare-ups after sex, and perimenstrual exacerbations of pain.[10] A study by Clemons et al[11] showed that among women with CPP, 38% (17/45) were diagnosed with IC. In addition, a recent retrospective study[12] of 60 patients with CPP found that at least 80% (48/60) of patients had both endometriosis and IC, suggesting that these disorders frequently overlap in patients with CPP. Differences in the rates of IC diagnosis between studies may be due to differences in patient populations or in the criteria used for diagnosis. Diagnosis of IC can be difficult; however, several methods are available to facilitate an accurate diagnosis. A simple questionnaire called the Pelvic Pain and Urgency/Frequency (PUF) patient symptom scale can be used as an effective screening tool to identify patients suspected of having IC.[13] The PUF questionnaire is an 8-question symptom scale that measures the presence and severity of symptoms on a scale of 1 to 35, and the extent to which each patient is bothered by those symptoms. A score of ≥15 is highly suggestive of IC. The PUF questionnaire may also be used to assess patient outcomes after therapy. This questionnaire has been validated by the Potassium Sensitivity Test (PST), which is used to confirm the presence of IC.[13] The PST involves instilling a solution containing potassium chloride (KCl) into the bladder and assessing symptoms. A study by Parsons et al[14] found increased bladder sensitivity to potassium, a marker for IC, in 85% (114/134) of patients with pelvic pain. In addition, cystoscopy has been shown to be effective in confirming the presence of IC with pathologic evidence such as glomerulations or Hunner's ulcers, or both.[11] Once IC is diagnosed, effective treatments are available, including oral therapy with pentosan polysulfate sodium (PPS).[15-18] Changes in diet and avoidance of certain foods may also help to lessen symptom severity in some patients.[19] In advanced cases, multimodal therapy with hydroxyzine, amitriptyline, gabapentin, or narcotics may be used for further symptom relief.[20-22] Cystoscopic hydrodistention (CH) and instillation therapy with dimethyl sulfoxide and other agents are additional useful treatment modalities for acute flare-ups of IC.[19,20]

METHODS

A study to investigate the prevalence of bladder-origin pain/IC in patients with posthysterectomy CPP, and to evaluate the efficacy of various treatment regimens including dietary modification, PPS, or CH, or both PPS and CH together, was conducted from October 2000 to November 2002 at the Midwest Regional Center for Chronic Pelvic Pain in Lima, Ohio. This study included 111 patients (age range, 34 to 65 years) with persistent or recurrent pelvic pain who had undergone hysterectomy with or without oophorectomy for the treatment of CPP from 1979 to 2001. All patients were evaluated using the PUF questionnaire, a PST, and a physical examination to identify lower abdominal, anterior vaginal wall tenderness, or bladder tenderness, or both. The PST involved first instilling 40 mL of water and then 40 mL of 0.4 M KCl for 5 minutes each. Subjective responses of urinary urgency or pain were recorded on a scale of 0 to 5. A provocation of symptoms resulting in an increase of 2 or more on either scale was considered positive.[23] Confirmation of IC by cystoscopy was based on the National Institutes of Health-National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK) guidelines.[24] Regardless of PUF or PST results, all patients were counseled regarding changes in diet, such as elimination of hot or spicy foods and foods high in potassium. Patients were also asked to follow a low-acid /low-oxalate diet. Those patients with a positive PST were offered treatment with either dietary modification alone or dietary modification in combination with CH (the bladder was distended for at least 2 minutes with sterile water under 80 cm to 100 cm of hydrostatic pressure), or oral therapy with PPS (200 mg bid), or both (. Patients who had a negative PST but experienced severe pain were treated with dietary modification in addition to CH (. Patients were followed up for at least 6 months (range, 6 to 25) and improvements were noted by changes from baseline PUF scores. Potassium Sensitivity Test results and treatment decisions. CH=cystoscopic hydrodistention; PPS=pentosan polysulfate sodium; PST=Potassium Sensitivity Test.

RESULTS

Irritative voiding symptoms were present in 94% (104/ 111) of patients. The mean PUF score at presentation was 14.47, and 57% (63/111) of patients had a PUF score of 14 or higher. Eighty-eight (79%) patients had a positive PST response, indicating bladder dysfunction consistent with IC. Of the 66 patients who went on to receive CH, 92% (61/66) had cystoscopic evidence of IC. Only 3 of the patients with a positive PST who went on to receive CH had no cystoscopic evidence of IC. Of the 10 patients who had a negative PST and opted for CH, 9 had cystoscopic evidence of IC. Of the 23 (21%) patients with a negative PST, 10 (9%) were treated with dietary modification alone, 10 (9%) were treated with dietary modification plus CH, and 3 (3%) were treated with dietary modification plus PPS. Of the 88 (79%) patients with a positive PST, 23 (21%) were treated with dietary modification alone and 88 (79%) were treated with dietary modification in combination with PPS or CH, or both (. Fifty-two patients received both PPS and CH. Nine patients received PPS alone and 4 patients received CH alone. The follow-up period was at least 6 months. shows mean PUF scores before and after treatment irrespective of PST result. For patients treated with dietary modification alone, the mean PUF score decreased from 13.18 at baseline to 11.15 at follow-up, an improvement of 15.4% (. Mean PUF scores for patients treated with PPS or CH, or both, plus dietary modification were 15.01 at baseline and 9.87 after therapy, an improvement of 34.2%, which is nearly double the improvement compared with the improvement in the group treated with dietary modification alone. Mean PUF Scores Before and After Treatment Regardless of PST Result* CH = cystoscopic hydrodistention; PPS = pentosan polysulfate sodium; PST = Potassium Sensitivity Test; PUF = Pelvic Pain and Urgency/Frequency. A decrease in score on the PUF questionnaire indicates symptom improvement.

DISCUSSION

Chronic pelvic pain is a common condition with numerous potential causes that are often difficult to diagnose and treat. Patients with CPP of bladder origin are often misdiagnosed and undergo multiple diagnostic and surgical procedures resulting in little or no symptom relief.[19] Until recently, IC has largely been ignored and considerably underdiagnosed as a cause of CPP. If the diagnosis of IC is not considered before surgery, hysterectomies may be performed unnecessarily in women with CPP. Accurate diagnosis and nonsurgical treatment of IC may relieve the symptoms of CPP. In this study, approximately 80% of women with persistent posthysterectomy CPP were diagnosed with bladder dysfunction based on the PST. Of the patients who received CH as part of their therapy, 80% had both a positive PST response and cystoscopic evidence of IC. Patients who were treated with CH or oral PPS, or both, showed improvement in bladder-related symptoms after 3 to 6 months, as evaluated with the PUF questionnaire. Even women who were treated with a low-potassium diet alone showed some improvement in bladder symptoms, although improvement was not as great as that with CH or PPS. These results suggest that bladder dysfunction may have been the source of pain for many of these women with posthysterectomy CPP. Other studies have also found that the prevalence of IC in patients with CPP is notable, suggesting that IC should be considered a primary diagnosis in these patients.[2,11,12,14] Based on a review of the literature and results of the recently completed study, it is recommended that gynecologists rule out nongynecologic causes of pain before performing a hysterectomy in patients with CPP. Proper evaluation for bladder dysfunction, including a thorough medical history and physical examination to assess bladder tenderness, is critical to making an accurate diagnosis. In the study presented here, 92% (81/88) of patients with positive PST also had positive CH. This suggests that positive PST may be sufficient for a diagnosis of IC. Cystoscopy with hydrodistention may be used for diagnosis of IC in patients with a negative PST and significant pelvic pain and bladder tenderness. If the bladder is determined to be the source of pelvic pain, proper treatment of IC with PPS in combination with other therapies may result in effective relief of pelvic pain and urinary symptoms, thereby avoiding unnecessary surgery.
Table 1.

Symptom Improvement Data From the Maryland Women's Health Study (N = 1299)*[8]

SymptomBefore HysterectomyPostoperative Follow-Up
1 Year2 Years
Vaginal bleeding59.20.50.3
Pelvic pain63.18.57.8
Back pain43.146.417.4
Activity limitation57.54.12.4
Sleep disturbance40.921.820.6
Fatigue70.026.724.7
Abdominal bloating47.813.512.1
Urinary incontinence19.58.58.3

Values are percentages unless otherwise indicated.

Table 2.

Mean PUF Scores Before and After Treatment Regardless of PST Result*

PUF ScoreAll Patients (n = 111)PPS and/or CH + Diet (n = 78)Diet Alone (n = 33)
Baseline14.4715.0113.18
Follow-up (≥6 mo)10.259.8711.15
Improvement, %29.234.215.4

CH = cystoscopic hydrodistention; PPS = pentosan polysulfate sodium; PST = Potassium Sensitivity Test; PUF = Pelvic Pain and Urgency/Frequency.

A decrease in score on the PUF questionnaire indicates symptom improvement.

  21 in total

Review 1.  Interstitial cystitis: a pathophysiology and treatment update.

Authors:  Robert M Moldwin; Grannum R Sant
Journal:  Clin Obstet Gynecol       Date:  2002-03       Impact factor: 2.190

2.  Safety and efficacy of up to 900 mg/day polysulfate sodium (elmiron) in patients with interstitial cystitis.

Authors:  J C Nickel; J Forrest; J Barkin; C Payne; P Mosbaugh
Journal:  Urology       Date:  2001-06       Impact factor: 2.649

3.  Gynecologic presentation of interstitial cystitis as detected by intravesical potassium sensitivity.

Authors:  C L Parsons; M Bullen; B S Kahn; E J Stanford; J J Willems
Journal:  Obstet Gynecol       Date:  2001-07       Impact factor: 7.661

4.  The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis.

Authors:  C L Parsons; M Greenberger; L Gabal; M Bidair; G Barme
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

5.  Hydroxyzine therapy for interstitial cystitis.

Authors:  T C Theoharides; G R Sant
Journal:  Urology       Date:  1997-05       Impact factor: 2.649

6.  Effectiveness of hysterectomy.

Authors:  K H Kjerulff; P W Langenberg; J C Rhodes; L A Harvey; G M Guzinski; P D Stolley
Journal:  Obstet Gynecol       Date:  2000-03       Impact factor: 7.661

Review 7.  Amitriptyline in the treatment of interstitial cystitis.

Authors:  P M Hanno
Journal:  Urol Clin North Am       Date:  1994-02       Impact factor: 2.241

8.  Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates.

Authors:  S D Mathias; M Kuppermann; R F Liberman; R C Lipschutz; J F Steege
Journal:  Obstet Gynecol       Date:  1996-03       Impact factor: 7.661

9.  The Maine Women's Health Study: I. Outcomes of hysterectomy.

Authors:  K J Carlson; B A Miller; F J Fowler
Journal:  Obstet Gynecol       Date:  1994-04       Impact factor: 7.661

10.  Diagnosing interstitial cystitis in women with chronic pelvic pain.

Authors:  Jeffrey L Clemons; Lily A Arya; Deborah L Myers
Journal:  Obstet Gynecol       Date:  2002-08       Impact factor: 7.661

View more
  6 in total

1.  Hysterectomies and Urologic Symptoms: Results from the Boston Area Community Health (BACH) Survey.

Authors:  Carol L Link; Samantha J Pulliam; John B McKinlay
Journal:  Female Pelvic Med Reconstr Surg       Date:  2010-01       Impact factor: 2.091

2.  A cohort study of interstitial cystitis/bladder pain syndrome and hysterectomy.

Authors:  Ming-Huei Lee; Kun-Min Chang; Shang-Liang Wu; Hsuan-Hung Lin; Hsiu-Ying Lin; Huei-Ching Wu
Journal:  Int Urogynecol J       Date:  2016-03-04       Impact factor: 2.894

3.  Cystoscopic findings in women with minimal and maximal lower urinary tract symptoms.

Authors:  Ioana Marcu; Jeffrey A Gavard; Golnar Vazirabadi; Joe Y Shi; Andrew C Steele; Fah Che Leong; Mary T McLennan; Jennifer A Bickhaus; Mary B Holloran-Schwartz; Patrick Yeung; Eugen C Campian
Journal:  Transl Androl Urol       Date:  2021-07

Review 4.  Early identification of interstitial cystitis may avoid unnecessary hysterectomy.

Authors:  Maurice K Chung; Barry Jarnagin
Journal:  JSLS       Date:  2009 Jul-Sep       Impact factor: 2.172

5.  The relationship between interstitial cystitis and endometriosis in patients with chronic pelvic pain.

Authors:  John D Paulson; Melissa Delgado
Journal:  JSLS       Date:  2007 Apr-Jun       Impact factor: 2.172

Review 6.  Patients with chronic pelvic pain: endometriosis or interstitial cystitis/painful bladder syndrome?

Authors:  Charles W Butrick
Journal:  JSLS       Date:  2007 Apr-Jun       Impact factor: 2.172

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.